drugset / Trial / NCT01530464

The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers

NCT01530464

Phase 1 Completed 18 enrolled Thies Schroeder
RandomizedCrossoverOpen-labelTreatment

Summary

This is a Phase I, three period, two sequence, open-label, randomized, crossover study, with the primary objective of testing the safety and tolerability of combined oral doses of aminophylline and ambrisentan in healthy human subjects. The secondary objective is to assess the pharmacokinetic profiles of theophylline (aminophylline) and ambrisentan when administered alone or in combination. It is hypothesized that the combination of these drugs is generally safe, and that no drug interaction can be observed.

Timeline

Start
2012-02
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ambrisentan Small molecule 5 mg Oral
Comparator Aminophylline Small molecule 500 mg Oral